P05
It is the unknown that defines our existence. We are constantly searching, not just for answers to our questions, but for new questions. We are explorers.

Latest

25
Apr
How a 12th-Century Financial Instrument Built a $50 Billion Asset Class

How a 12th-Century Financial Instrument Built a $50 Billion Asset Class

In November 1158, on the plains outside Piacenza, Emperor Frederick Barbarossa convened the Diet of Roncaglia to reassert imperial authority
24 min read
24
Apr
Company of the week: Kazia Therapeutics

Company of the week: Kazia Therapeutics

Kazia Therapeutics is a Sydney, Australia-based clinical-stage oncology company developing therapies designed to reprogram cancer biology and overcome treatment resistance.
27 min read
23
Apr
Fund of the week: OMERS Life Sciences

Fund of the week: OMERS Life Sciences

Fund Snapshot Firm OMERS Life Sciences (division of OMERS Capital Markets) Parent Ontario Municipal Employees Retirement System (OMERS) Established 2016
23 min read
22
Apr
The Co-Funding Royalty: Phase III Co-Investment, Synthetic Revenue Interests, and How BD Teams Position the Hybrid Proposal

The Co-Funding Royalty: Phase III Co-Investment, Synthetic Revenue Interests, and How BD Teams Position the Hybrid Proposal

Somewhere between a licence, a loan, and an equity investment — but structurally none of these — sits a transaction type that
15 min read
21
Apr
Medical Device Royalty Financing: Deal Mechanics, Structural Precedent, and Royalty-Readiness Thresholds

Medical Device Royalty Financing: Deal Mechanics, Structural Precedent, and Royalty-Readiness Thresholds

Pure medical device royalty monetization remains a small segment of the life sciences non-dilutive capital market. Of Gibson Dunn'
15 min read
20
Apr
Why Norway Does Not Have a Pharmaceutical Royalty Fund Yet

Why Norway Does Not Have a Pharmaceutical Royalty Fund Yet

Notes from the 7th Norwegian Life Science Investor Partnering Day on what Norway has, what is missing, and how a Norwegian pharmaceutical royalty fund could actually be put together.
13 min read
19
Apr
The Weekly Term Sheet (2026-W16)

The Weekly Term Sheet (2026-W16)

W16 opened with Friday holdovers and closed with a Friday evening headlined by UCB's up to $1.15
102 min read
18
Apr
The Tax Architecture of Royalty Funds: How Jurisdiction Shopping Shapes Pharmaceutical Finance

The Tax Architecture of Royalty Funds: How Jurisdiction Shopping Shapes Pharmaceutical Finance

When Royalty Pharma filed its S-1 prospectus ahead of its 2020 IPO, the organizational chart told a story that no
21 min read
17
Apr
Company of the week: Opus Genetics

Company of the week: Opus Genetics

Opus Genetics is a Research Triangle Park, North Carolina-based clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs)
22 min read
16
Apr
Fund of the week: Jeito Capital

Fund of the week: Jeito Capital

Fund Snapshot Firm Jeito Capital Fund I Jeito I, €534M ($630M), final close September 2021 Fund II Jeito II, >
19 min read